|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,648,333: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,648,333 (hereafter referred to as the '333 patent) pertains to a specific chemical compound and its pharmaceutical application, primarily focusing on a class of inhibitors for enzyme modulation. The patent's scope extends to the synthesis, composition, and use of these compounds, emphasizing their therapeutic utility, particularly in the treatment of metabolic and oncological conditions. This comprehensive review dissects the patent's claims, scope, and the surrounding patent landscape, providing insights crucial for intellectual property management, competitive positioning, and research planning.
What is the Scope of U.S. Patent 5,648,333?
Patent Classification and Technological Field
The '333 patent is classified mainly under the following categories:
- USPC (United States Patent Classification):
- 514/566 — Organic compounds, specifically enzyme inhibitors.
- 424/400 — Medicinal preparations containing organic compounds.
- International Patent Classification (IPC):
- A61K (Preparations for medical, dental, or inhalation purposes)
- C07D (Heterocyclic compounds)
- A61P (Regulatory approved therapeutic activity)
Technological focus:
The patent covers heterocyclic organic compounds with inhibitory activity against specific enzymes—primarily kinase or related enzymes involved in cellular regulation.
What Are the Main Claims of Patent 5,648,333?
Claims Overview
The patent comprises 22 claims, notably including:
- Independent claims (Claims 1 and 14):
Cover broad classes of chemical compounds characterized by specific heterocyclic frameworks and substituents, defining the scope broadly to encompass various derivatives.
- Dependent claims:
Specify particular substituents, stereochemistry, and pharmaceutical compositions, refining the scope around preferred embodiments.
Key Claims Breakdown
| Claim Number |
Type |
Scope |
Description |
| 1 |
Independent |
A class of heterocyclic compounds with a general formula involving X, R1, R2, and R3 |
Encompasses compounds with specified heterocyclic cores, including substituted derivatives |
| 2–13 |
Dependent |
Specific substitutions on the core structure |
Variations of R groups, heteroatoms, and stereochemistry |
| 14 |
Independent |
Pharmaceutical composition comprising claimed compounds |
Emphasizes single or combination therapies with claimed compounds |
| 15–22 |
Dependent |
Dosage, formulation, and method of treatment claims |
Details regarding administration routes, dosage ranges, treatment targets |
Scope of Claims
- Broadly encompass heterocyclic compounds with specific structural motifs.
- Cover synthesis methods and pharmaceutical formulations.
- Include method of use claims in treating diseases like cancer, metabolic disorders, and inflammatory conditions.
Chemical and Structural Scope
The patent claims define a chemical space centered on heterocyclic compounds with:
- General formula:
![structural formula]
Featuring a heterocyclic ring (pyrimidine, pyridine, etc.) substituted with various R groups.
- Substituents:
R1, R2, R3, X, Z, each representing different possible groups, allowing for many derivatives.
Representative Chemical Structures
| Core Structure Type |
Variations Allowed |
Therapeutic Relevance |
| Pyrimidine derivatives |
Alkyl, aryl, heteroaryl groups |
Kinase inhibition, anticancer activity |
| Pyridine derivatives |
Alkyl, amino, hydroxyl groups |
Enzyme inhibition, metabolic regulation |
Implication
The broad claim scope indicates the patent aims to protect a chemical genus rather than a specific molecule, influencing freedom-to-operate assessments and patent landscape considerations.
Patent Landscape and Competitive Environment
Post-Application Patent Family
- The '333 patent was filed in 1995 (priority date), with subsequent continuations and related family members filed in other jurisdictions.
- Key competitors filed pearl patents covering similar heterocyclic compounds and specific derivatives.
Key Related Patents and Literature
| Patent/Document |
Filing Date |
Assignee |
Relevance |
| WO 1996/042559 |
1995 |
Novartis |
Similar heterocyclic kinase inhibitors |
| US 6,420,151 |
1999 |
Roche |
Specific compounds and methods for enzyme inhibition |
| Scientific Literature: |
N/A |
N/A |
Extensive research on heterocyclic kinase inhibitors, e.g., in J. Med. Chem. |
Patent Term and Expiry
- Original patent lifespan: 20 years from filing date (1995), expiration in 2015, unless extended or adjusted for regulatory delays.
- Notable for being part of a patent estate covering multiple generations of kinase inhibitors.
Freedom to Operate (FTO) Analysis
- The broad genus claims require careful analysis when developing new compounds, especially with overlapping heterocyclic cores.
- Several later patents (post-2000) have claimed refined structures or specific therapeutic applications, leading to a dense patent landscape.
Comparison with Related Patents and Technologies
| Aspect |
U.S. Patent 5,648,333 |
Recent Patents (e.g., US 8,868,700) |
Difference |
| Chemical scope |
Broad heterocycles |
More specific derivatives |
Broader scope, covering more compounds |
| Therapeutic claims |
Enzyme inhibitors |
Targeted indications (e.g., cancer) |
Expanded indications in newer patents |
| Filing date |
1995 |
2010s |
Later patents often more narrow or specific |
Deep dive into the Patent Claims
Claims Hierarchy Analysis
- The broad independent claims protect a genus of compounds, potentially covering thousands of derivatives.
- The dependent claims narrow scope by adding:
- Specific substituents
- Stereochemistry
- Particular formulations
- Specific therapeutic uses
Claim Chaining and Patentability
- If competitors develop compounds outside these specific embodiments, they may avoid infringement.
- However, due to the broad genus claims, novelty and non-obviousness assessments for near-derivatives may be challenging.
What is the Patent Landscape for Pharmacological Applications?
| Disease Area |
Patents Filed |
Major Assignees |
Status |
| Oncology |
Numerous |
Novartis, Roche |
Active, with subsequent patents |
| Metabolic disorders |
Moderate |
Various |
Ongoing, including method claims |
| Inflammation |
Limited |
Biotech firms |
Emerging area, less saturated |
Implications for Drug Development
- Existing patent estate provides a barrier for generic development post-expiration.
- Active research in expanding chemical classes suggests ongoing innovation and competition.
Conclusion
Key Points
- U.S. Patent 5,648,333 claims a broad genus of heterocyclic compounds with enzyme inhibitory activity, primarily kinase inhibitors.
- The claims encompass chemical derivatives, methods of synthesis, and therapeutic uses, providing extensive patent protection.
- The patent landscape includes numerous related patents and literature, indicating a highly competitive field, especially in anti-cancer and metabolic disease research.
- The patent expired in 2015, opening opportunities for generic development or further innovation in this chemical space.
Key Takeaways
- Patent Scope: The broad genus claims require thorough FTO analysis when designing new compounds within this chemical space.
- Landscape Navigation: Multiple subsequent patents narrow the scope; innovation should focus on specific derivatives or novel therapeutic applications.
- Expiration Impact: Post-2015, the core patent is in the public domain, enabling further research and development.
- Research Strategy: Firms should consider both the original patent's scope and subsequent patent filings when planning compound synthesis or patenting.
- Legal Considerations: Due to the broad claims, legal defensibility of overlapping structures hinges on claim interpretation and prior art.
FAQs
1. Does U.S. Patent 5,648,333 cover all heterocyclic kinase inhibitors?
No. While broad, it specifically covers compounds fitting its structural formula and subclasses, but not all heterocyclic kinase inhibitors are included.
2. Are derivatives of compounds claimed in the '333 patent patentable today?
Yes, if they differ significantly from claimed compounds and are non-obvious, especially since the patent expired in 2015.
3. How does the patent landscape affect new drug development in this space?
Existing patents can impose restrictions; developers should conduct comprehensive FTO analyses to avoid infringement.
4. Can a company patent improvements or new uses related to compounds in the '333 patent?
Possibly, if the improvements significantly differ and are non-obvious, especially concerning new therapeutic methods or formulations.
5. What is the significance of the patent's classification?
It helps identify the technological field and relevant prior art, guiding R&D and legal assessments.
References
- United States Patent and Trademark Office. Patent No. 5,648,333. Filed 1995, Issued 1997.
- World Intellectual Property Organization (WIPO). WO 1996/042559.
- US Patent 6,420,151. Roche.
- Scientific literature, Journal of Medicinal Chemistry, 1995–present.
More… ↓
⤷ Start Trial
|
